Thelansis’s "Hunter Syndrome (Mucopolysaccharidosis Type II) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hunter Syndrome (Mucopolysaccharidosis Type II) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Hunter syndrome (Mucopolysaccharidosis Type II, or MPS II) is a rare, X-linked recessive lysosomal storage disorder caused by a deficiency in the iduronate-2-sulfatase (IDS) enzyme. This mutation prevents the breakdown of complex sugars called glycosaminoglycans (GAGs)—specifically heparan sulfate and dermatan sulfate—causing toxic intracellular accumulation. Affecting almost exclusively males, the systemic presentation includes coarse facial features, joint contractures, hepatosplenomegaly, and progressive cardio-respiratory complications. Crucially, about 70% of patients manifest the severe neuronopathic form, facing relentless neurocognitive decline. While traditional enzyme replacement therapy (idursulfase) manages peripheral organs, it cannot cross the blood-brain barrier (BBB). The therapeutic paradigm shifted profoundly in March 2026 with the FDA’s accelerated approval of Avlayah (tividenofusp alfa-eknm). This first-in-class biologic hijacks transferrin-receptor transcytosis to actively cross the BBB, reducing cerebrospinal fluid heparan sulfate by 91% to treat neurological manifestations. Additionally, advanced therapeutics are evolving rapidly; Regenxbio is preparing a Q3 2026 BLA resubmission for its one-time gene therapy Navsunli (clemidsogene lanparvovec) following a highly favorable FDA regulatory pivot. Ultimately, early identification via newborn screening combined with these modern, central nervous system-penetrating modalities is radically redefining long-term patient outcomes.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Hunter Syndrome (Mucopolysaccharidosis Type II) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Hunter Syndrome (Mucopolysaccharidosis Type II) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.